WO2016010183A1 - Composition for improving lipid-related metabolism comprising as active ingredient exopolysaccharide derived from extract from culture medium of ceriporia lacerata - Google Patents

Composition for improving lipid-related metabolism comprising as active ingredient exopolysaccharide derived from extract from culture medium of ceriporia lacerata Download PDF

Info

Publication number
WO2016010183A1
WO2016010183A1 PCT/KR2014/006826 KR2014006826W WO2016010183A1 WO 2016010183 A1 WO2016010183 A1 WO 2016010183A1 KR 2014006826 W KR2014006826 W KR 2014006826W WO 2016010183 A1 WO2016010183 A1 WO 2016010183A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
weight
lipid
extract
paragraph
Prior art date
Application number
PCT/KR2014/006826
Other languages
French (fr)
Korean (ko)
Inventor
김지은
김윤수
윤성균
김병천
박용만
Original Assignee
(주)퓨젠바이오농업회사법인
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)퓨젠바이오농업회사법인 filed Critical (주)퓨젠바이오농업회사법인
Publication of WO2016010183A1 publication Critical patent/WO2016010183A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/14—Yeasts or derivatives thereof
    • A23L33/145—Extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • C12P1/02—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using fungi
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi

Definitions

  • composition for improving metabolism related to lipids containing extracellular polysaccharide derived from the extract of Seriphoria laccerata culture solution Field of the Invention The present invention is derived from the extract of the mycelium culture medium (e po a lacerata)
  • the present invention relates to a composition for improving lipid metabolism or preventing or treating lipid-related metabolic diseases containing an extracellular polysaccharide as an active ingredient.
  • Tumors and heart disease are the leading causes of death among Koreans, and pediatric and adult diseases are also on the rise, which is a serious problem for the public health.
  • hyperlipidemia is a condition in which cholesterol or triglycerides are abnormally increased, and various inhibitors of cholesterol synthesis are being studied to improve hyperlipidemia. '
  • HMG—CoA reductase an enzyme that converts (3-hydr oxy-3-met hy 1 g 1 ut ar y 1 coenzyme A; HMG ⁇ CoA) to mevalonate It is a regulatory enzyme and a decrease in HMG-CoA reductase activity in the liver has been reported to increase the activity of LDL-receptors in the liver, thereby reducing the concentration of cholesterol in the blood (Si tory, C., Pharm. Res. 1990, 22, 555-562; Qureshi, AA et al. , Lipids. 1983, 18, 343-348; Qureshi, AA et al. Lipids. 1985, 20, 817-824).
  • lovastatin simvastatin (simvastat in), pravastatin, fluvastatin (f luvastatin) atorvastatin and sevastatin (cervastatin) Statins.
  • Statins can inhibit the synthesis of cholesterol in vivo and consequently significantly lower cholesterol, but involve side effects such as severe muscle pain. Therefore, studies are actively underway to find bioactive substances that inhibit cholester synthesis without side effects.
  • Ceriporia lacserata (Ce / wr / a lacerata) is a white fungus that co-metabolizes lignin decomposition to use carbon sources such as cellulose, hemicellose, other polysaccharides and glycerol in the ecosystem. It is known to carry out. However, since the existence of Ceriporia lacserata was first reported to ME in 2002, research on its industrialization is still insignificant. Specifically, the "application for the prevention and treatment of diabetic disease” filed by the present inventors has been insignificant. Method of preparing liporia lacserata culture extract and according to the Korean Patent No. 10-1031605 regarding "Seriphoria lacserata culture extract" It is enough.
  • an object of the present invention is to contain a natural substance derived from the extract of Seriphoria laccerata mycelium culture medium as an active ingredient. To improve lipid-related metabolism, It is to provide a composition for preventing or treating lipid-related metabolic diseases.
  • Another object of the present invention is to provide a foodstuff for improving metabolism related to lipids, which contains a natural substance derived from the extract of Ceriporia laccerata mycelia.
  • the present invention provides a composition for improving lipid-related metabolism containing an extracellular polysaccharide derived from the extract of the seriporia laccerata mycelium culture solution as an active ingredient.
  • the present invention provides a composition for the prevention or treatment of lipid-related metabolic diseases containing the extracellular polysaccharide derived from the extract of the seriporia laccerata mycelium culture medium as an active ingredient.
  • the extracellular polysaccharide may be included.
  • the lipid-related metabolic disease may be fatty liver, hyperlipidemia, hypercholesterolemia, cardiovascular disease, arteriosclerosis or lipid-related metabolic syndrome.
  • the present invention provides a food-related lipid-improving metabolism containing the extracellular polysaccharide derived from the extract of the seriporia laccerata mycelium culture.
  • the composition containing the extracellular polysaccharide derived from the extract of Seriporia laccerata mycelium culture medium according to the present invention as an active ingredient can be very effectively used for improving lipid-related metabolism and preventing or treating lipid-related metabolic diseases.
  • 1 is a graph measuring the molecular weight of EPS according to the culture purification.
  • the present invention is Ceriporia lac serrata; r / a lacerata) Provides a composition for improving lipid-related metabolism containing an extracellular polysaccharide (exopo lysacchar ide; EPS) derived from the mycelium culture extract.
  • EPS extracellular polysaccharide
  • the present invention provides a composition for the prevention or treatment of lipid-related metabolic diseases, containing the extracellular polysaccharide derived from the extract of the seriporia laccerata mycelium culture medium as an active ingredient.
  • the extracellular polysaccharide is about 40-60% by weight of sugar and about 30-40% by weight protein, about 40-50% by weight of sugar and about 32-38% by weight of protein or about 43-47 wt% sugar and about 33-36 wt% protein, and preferably about 45 wt% sugar and about 34 wt% protein.
  • the sugar may contain mannose, galactose and glucose.
  • the extracellular polysaccharide may have a molecular weight of about 100-150 kDa, about 110-140 kDa or about 115-125 kDa, and preferably may have a molecular weight of about 120 kDa.
  • the extracellular polysaccharide is (a) liquid culture of the Ceriporia laccerata mycelium to prepare a culture medium of Ceriporia laccerata other mycelium, (b) Ceriporia laccerata mycelium
  • the culture solution may be prepared by drying the powder, and (c) extracting the Ceriphoria laccerata mycelium culture powder with a solvent, followed by filtration and concentration under reduced pressure.
  • Liquid culture of the seriporia lacserata mycelium in step (a) contains sugar, glucose, starch, hydrate, soy flour, soy flour, magnesium sulfate (MgS0 4 ), potassium phosphate (K3 ⁇ 4P0 4 ), potassium diphosphate (K 2 HP0 4 ) and water, and hydrogen ion concentration May be ⁇ 4.5-6.0.
  • the sugar 1-2% by weight, 0.2 to 1% by weight glucose, starch, 0.2 to 1 wt 3 ⁇ 4>, moisture can 0. 1-0.5% by weight, barley 0. 1-0.5 min Weight%, Soy flour 0.2-4 weight%, Magnesium sulfate (MgS0 4 ) 0.05 ⁇ 0.25 increase 3 ⁇ 4, potassium phosphate (K3 ⁇ 4P0 4 ) 0.05 ⁇ 0.25 weight potassium diphosphate ( ⁇ 0 4 ) 0.05 ⁇ 0.25 weight 3 ⁇ 4 and water It may comprise 92 to 98% by weight.
  • the liquid culturing in step (a) may be performed under a blue LED light source, and may be performed by maintaining a concentration of carbon dioxide at 1,000-2, ⁇ .
  • the liquid culture at 20 ⁇ 25 ° C, hydrogen ion concentration (pH) 4.5-6.0, light source blue LED, illuminance maintains 0.5 LUX
  • air is injected into 0.5-1.5 kgf / cm 2 and the concentration of carbon dioxide It can be carried out for 8 to 13 days while maintaining at 1, 000 2,000 ppm, and 10 days at 22 ° C, pH5, 1.0 kgf / cm 2 , 1, 500 ppm conditions because of the high content of extracellular polysaccharides desirable.
  • the parent strain in the step (a) is a good strain stored at 4 ° C in the state of PDA (Po to dextrose agar) medium, 25 ° in shake incubator using PDB (Potato dextrose broth) medium in the Erlenmeyer flask It can be used to maintain a constant temperature of C and after 7 to 9 days incubation process.
  • the amount of mycelia to be added to the inoculum is preferably about 0.5% based on the amount of the solution to be cultured.
  • the culture medium may be separated and purified by the mycelium and the aqueous solution
  • the separated purification is a multi-filter press (Mul t i-Sheet) to remove the mycelium with a centrifuge
  • UV Vibration Centrifuge
  • the mycelia culture solution prepared in step) may be powdered by vacuum drying or lyophilization.
  • the drying is preferably carried out for 48 to 96 hours at a low temperature of 40 ° C or less, preferably 30 ° C or less in order to prevent the disappearance of the active substance.
  • step (c) the mycelium culture broth obtained in step (b) is extracted with a solvent to separate and prepare an extracellular polysaccharide which is an active ingredient of the composition according to the present invention.
  • the above process is suspended by adding 100 mL of distilled water to 5 g of dry powder, followed by centrifugation (8,000 rpm, 20 min) to add 2 ⁇ 3 times the amount of cold alcohol to the supernatant thereof. I can put it in django (41 :) and let it stand for 12 hours. After centrifugation (8, 000 rpm, 20 min) again only the supernatant from the stationary material, the precipitate can be recovered to prepare a crude extracellular polysaccharide.
  • the extract is preferably freeze dried in 3C C or less.
  • Suitable carriers, excipients, and diluents commonly used in compositions for the improvement of lipid-related metabolism or for the prevention or treatment of lipid-related metabolic diseases which contain extracellular polysaccharides derived from the extract of Ceriporia laccerata mycelium culture medium according to the present invention. More crabs may be included.
  • the extracellular polysaccharide may be included in an amount of 0.1 to 80% by weight, preferably 0.1 to 50% by weight, based on the total weight of the composition.
  • the effective amount of the most preferred extract can be properly adjusted according to the method of use and purpose of the composition.
  • compositions according to the present invention can be used to formulate, according to a conventional method, respectively.
  • suitable formulations include, but are not limited to, tablets, pills, powders, granules, dragees, hard or soft capsules, solutions, suspensions or emulsions, injections, suppositories, and the like.
  • the composition according to the invention can be prepared in a suitable formulation using a pharmaceutically inert organic or inorganic carrier. That is, lactose, sucrose, starch or derivatives thereof, talc, calcium carbonate, gelatin, stearic acid or salts thereof may be used when the formulation is tablets, coated tablets, dragees and hard capsules.
  • polyols of vegetable oils, waxes, fats, semisolids and liquids can be used when the formulation is a soft capsulant.
  • water, poly, glycerol, and vegetable oil spouts may be used when the formulation is in solution or syrup form.
  • composition according to the present invention may further include a preservative, stabilizer, wetting agent, emulsifier, solubilizer, sweetener, coloring crab, osmotic pressure control agent, antioxidant and the like in addition to the carrier.
  • the method of administering the composition according to the present invention can be easily selected according to the dosage form, and can be administered orally or parenterally.
  • the dosage may vary depending on the patient's age, sex, severity of the disease and the route of administration, but in general, the amount of 5 to 500 mg / kg, preferably 100 to 250 mg / kg, divided once to 3 times a day May be administered.
  • the above dosage does not limit the scope of the present invention in any aspect.
  • composition according to the present invention not only provides an excellent lipid-related metabolic improvement effect but also has little toxicity and side effects due to the drug, and thus can be used safely for long-term administration as well as for the purpose of preventing lipid-related metabolic diseases.
  • the lipid-related metabolic disease may be fatty liver, hyperlipidemia, hypercholesterolemia, cardiovascular disease arteriosclerosis or lipid-related metabolic syndrome, but is not limited thereto.
  • the present invention provides a food for improving lipid-related metabolism, containing the extracellular polysaccharide derived from the extract of Seriphoria laccerata mycelium culture solution.
  • Food according to the invention may be in the form of powder, granules, tablets, capsules or beverages, candy, chocolate, beverages, gum, tea, vitamin complex dietary supplements or It may be a dietary supplement.
  • the extracellular polysaccharide according to the present invention in the food in general may be included in 0.01 to 50% by weight, preferably 0.1 to 20% by weight of the total food weight and 0.02 to 10g based on 100ml for the health beverage composition, Preferably it may be included in the ratio of 0.3 to lg.
  • the food may further comprise a food supplement acceptable food additives with the extracellular polysaccharide of the present invention.
  • a food supplement acceptable food additives with the extracellular polysaccharide of the present invention will be described in more detail with reference to the following examples. However, the following examples are only for illustrating the present invention, and the scope of the present invention is not limited thereto.
  • magnesium sulfate (MgS0 4 ) 0.05% by weight, Potassium phosphate (3 ⁇ 4P0 4 ) 0.05% by weight ⁇ 0.05% by weight of potassium diphosphate (K 2 HP0 4 ) and 96.85% by weight of water were added to a liquid culture medium at 800 ° C fermenter at 121 ° C, 1.5 kgf / cm 2 .
  • Ceriporia lacserata mycelium cultures were prepared by liquid incubating the lacserata mycelium at a constant temperature of 23 ° C. for 10 days.
  • the analytical conditions were the index of refraction and the GPC column was OHpak SB 805. Using HQ (Shodex, Japan), the mobile phase was flowed into 0.1 M Na 2 SO 4 /0.05 M NaN 3 (adjusted pH to 4 with glacial acetic acid) at a rate of 1.0 mL / min. Standard curves were prepared using Amer ican Polymer Corporation, USA, with different molecular weights (130, 400, 770, and 1200 kDa), and Knauer K_2310 (Germany), a refractive index (RI) measuring instrument. The molecular weight of EPS was measured (Table 1).
  • the molecular weight of EPS was found to be about 120 kDa (FIG. 1).
  • EPS was purified twice and treated with proteolytic enzymes to determine sugar and protein content.
  • the first purified EPS is dissolved again in distilled water and centrifuged (8,000rpm,
  • Sugar content was measured by the phenol- sulfuric acid method (pheno ⁇ sulfuric acid method). After adding 25 yL of 80% phenol to 1 raL of each sample diluted by concentration, 2.5 mL of sulfuric acid was added, and the mixture was absorbed at room temperature and the absorbance was measured at 465 nm. Protein content was measured by the BCA method (Smi th P, et al., Analytical Biochemistry, 150 (1): 76-85 (1985)) and bovine serum albumin was used as a standard.
  • the sugar content is 45 ⁇ 51% by weight and the protein content was found to be 33 ⁇ 34% by weight.
  • Angular values are mean ⁇ SE (n ⁇ 3).
  • EPS mainly contained mannose, galactose and glucose.
  • C57BL / Ksj (BL / Ls) homozygous di abet ic (db / db) mice were used.
  • the db / db mice used in this study were 30-40 g 6-week-old males, produced by Japan SIX Inc. It was supplied through experimental animal Co., Ltd. After the acclimation period, the body weight and blood glucose were measured to select 30 healthy animals suitable for the test and no abnormal symptoms.
  • the experimental animals were negative control ("DM group”), EPS low dose group (150 mg / kg, "DM-EX0150 group”), EPS high dose group (300 mg / kg, "DM-EX0300 group”) and positive control group (metformin ( Four groups, including metformin) -300 mg / kg and “DM-MET300 group”), were randomly divided so that the blood sugar and body weight were equally distributed for 6 weeks.
  • the normal control group (“NC group”) was also housed 6 animals for 6 weeks under the same conditions. All test and positive controls were orally administered at the same time every day, and normal and negative controls were orally administered with water.
  • the diet of experimental animals was supplied with commercial experimental animal solid feed (Samtaco co.
  • the breeding conditions of the animal breeding room were adjusted to have a 12-hour contrast cycle (lighting from 8 am to 8 pm), a temperature of 23 ⁇ 3 ° C, and a relative humidity of 50 ⁇ 10%. ⁇
  • Db / db mice 6 weeks after the EPS administration were regenerated and histologic morphological characteristics of the liver were observed and lipid levels in the blood were measured.
  • liver Histological Morphological Characteristics of Liver
  • the liver was stained with hematoxylin and eosin to observe the histologic morphological characteristics of the liver.
  • hepatic lipids increased sharply in the DM group, which was a negative control, while significantly decreased in the EPS administration group (ie, DM-EX0150 group and DM-EX0300 group) (FIG. 2).

Abstract

The present invention relates to a composition for improving lipid-related metabolism, or preventing or treating lipid-related metabolic disease, the composition comprising, as an active ingredient, an exopolysaccharide derived from an extract from the mycelial culture medium of Ceriporia lacerata. The exopolysaccharide derived from an extract from the mycelial culture medium of Ceriporia lacerata, according to the present invention, may be used as a composition for preventing or treating lipid-related metabolic disease by means of the great effect of improving lipid-related metabolism, and as a material for related food.

Description

명세서 세리포리아 락세라타 배양액 추출물 유래의 세포외다당체를 유효성분으로 함유하는 지질 관련 대사 개선용 조성물 발명의 분야 본 발명은 세리포리아 락세라타 ( ( e po a lacerata) 균사체 배양액 추출물 유래의 세포외다당체를 유효성분으로 함유하 ¾ 지질 관련 대사 개선 또는 지질 관련 대사성 질환의 예방 또는 치료용 조성물에 관한 것이다. 배경기술 고도의 산업화와 경제적 수준의 향상으로 식생활 패턴이 서구화되면서 뇌혈관계 질환, 악성 종양 및 심장 질환 .등이 최근 한국인의 사망 원인으로 높은 비중을 차지하고 있으며， 소아 성인병 또한 증가 추세에 있어 국민 보건에 심각한 문제점으로 지적되고 있다. 특히, 동물성 식품과 정제된 식품의 섭취량 증가는 지방간, 고지혈증, 고콜레스테를혈증, 심혈관 질환 동맥경화증 또는 지질 관련 대사증후군 등의 합병증을 수반한다.  Composition for improving metabolism related to lipids containing extracellular polysaccharide derived from the extract of Seriphoria laccerata culture solution Field of the Invention The present invention is derived from the extract of the mycelium culture medium (e po a lacerata) The present invention relates to a composition for improving lipid metabolism or preventing or treating lipid-related metabolic diseases containing an extracellular polysaccharide as an active ingredient. Tumors and heart disease are the leading causes of death among Koreans, and pediatric and adult diseases are also on the rise, which is a serious problem for the public health. Hyperlipidemia, hypercholesterolemia, cardiovascular disease arteriosclerosis or lipid related It is accompanied by complications such as metabolic syndrome.
이 중 고지혈증은 혈장 내 콜레스테를이나 중성지방이 비정상적으로 증가된 상태로서， 고지혈증 개선을 위해 콜레스테를 합성저해제가 다방면으로 연구되고 있다. ' Among them, hyperlipidemia is a condition in which cholesterol or triglycerides are abnormally increased, and various inhibitors of cholesterol synthesis are being studied to improve hyperlipidemia. '
콜레스테를 생합성 과정 중 3-하이드록시 -3ᅳ메틸글루타릴 코엔자임 A 3-hydroxy-3 ᅳ methylglutaryl coenzyme A during cholesterol biosynthesis
( 3-hydr oxy-3-me t hy 1 g 1 ut ar y 1 coenzyme A ; HMG一 CoA)로부터 메발로네이트 (meval onate)로 전환시키는 효소인 HMG— CoA 리덕타아제는 콜레스테롤 합성속도의 주요 조절 효소이며, 간 내에 HMG-CoA 리덕타아제 활성의 저하는 간의 LDL-수용체의 활성을 증가시켜 혈중 콜레스테를 농도를 감소시킨다고 보고되어 있다 (Si tory , C . . , Pharm. Res. 1990 , 22 , 555-562； Qureshi， A. A. et al . , Lipids. 1983, 18, 343-348； Qureshi， A. A. et al . Lipids. 1985， 20， 817-824 참조). HMG—CoA reductase, an enzyme that converts (3-hydr oxy-3-met hy 1 g 1 ut ar y 1 coenzyme A; HMG 一 CoA) to mevalonate It is a regulatory enzyme and a decrease in HMG-CoA reductase activity in the liver has been reported to increase the activity of LDL-receptors in the liver, thereby reducing the concentration of cholesterol in the blood (Si tory, C., Pharm. Res. 1990, 22, 555-562; Qureshi, AA et al. , Lipids. 1983, 18, 343-348; Qureshi, AA et al. Lipids. 1985, 20, 817-824).
이러한 고지혈증 및 고콜레스테를혈증의 치료제로서 최근 많이 사용되는 것은 로바스타틴 (lovastatin), 심바스타틴 (simvastat in)， 프라바스타틴 (pravastatin), 플루바스타틴 (f luvastatin)ᅳ 아토바스타틴 (atorvastatin) 및 세바스타틴 (cervastatin) 등의 스타틴 (statin)류의 물질이다. 스타틴류의 물질은 생체 내에서 콜레스테를의 합성을 저해하여 결과적으로 콜레스테롤 양을 현저히 낮출 수 있지만， 심각한 근육통 등의 부작용들을 수반한다. 따라서， 부작용 없이 콜레스테를 합성을 저해하는 생리활성물질을 찾아내려는 연구가 활발하게 진행되고 있다.  Recently used as a treatment for hyperlipidemia and hypercholesterolemia is lovastatin, simvastatin (simvastat in), pravastatin, fluvastatin (f luvastatin) atorvastatin and sevastatin (cervastatin) Statins). Statins can inhibit the synthesis of cholesterol in vivo and consequently significantly lower cholesterol, but involve side effects such as severe muscle pain. Therefore, studies are actively underway to find bioactive substances that inhibit cholester synthesis without side effects.
세리포리아 락세라타 (Ce /wr/a lacerata)는 백색 부후균의 일종으로서， 생태계에서 셀를로오스， 헤미 셀를로오스, 기타 다당류 및 글리세를 등의 탄소원을 이용하기 위하여 리그닌 분해라는 공동대사를 수행하는 것으로 알려져 있다. 그러나， 세리포리아 락세라타의 존재가 2002년 처음으로 학계에 보고된 이후 이의 산업화에 대한 연구는 아직 미미한 실정이다.구체적으로，본 발명자들에 의하여 출원된 "당뇨병 질환의 예방 및 치료를 위한 세리포리아 락세라타 배양액 추출물의 제조방법 및 이에 따른 세리포리아 락세라타 배양액 추출물 "에 관한 대한민국 특허 제 10-1031605호에 세리포리아 락세라타 배양액 추출물의 당뇨에 대한 치료 효과가 공개되어 있는 정도이다.  Ceriporia lacserata (Ce / wr / a lacerata) is a white fungus that co-metabolizes lignin decomposition to use carbon sources such as cellulose, hemicellose, other polysaccharides and glycerol in the ecosystem. It is known to carry out. However, since the existence of Ceriporia lacserata was first reported to academia in 2002, research on its industrialization is still insignificant. Specifically, the "application for the prevention and treatment of diabetic disease" filed by the present inventors has been insignificant. Method of preparing liporia lacserata culture extract and according to the Korean Patent No. 10-1031605 regarding "Seriphoria lacserata culture extract" It is enough.
이에， 본 발명자들은 세리포리아 락세라타 균사체 배양액 추출물을 대상으로 예의 연구를 계속한 결과， 세리포리아 락세라타 배양액 추출물 유래의 세포외다당체(6^1)01 3^(±&^( ； EPS)가 지질 관련 대사 개선 효과를 갖는 것을 발견함으로써， 본 발명을 완성하였다. , 발명의 요약 따라서， 본 발명의 목적은 세리포리아 락세라타 균사체 배양액 추출물 유래의 천연물질을 유효성분으로 함유하여 지질 관련 대사를 개선시키거나， 지질 관련 대사성 질환을 예방 또는 치료하는 조성물을 제공하는 것이다. Accordingly, the present inventors conducted a thorough study of the extract of the culture medium of the seriporia laccerata mycelium, and the extracellular polysaccharide (6 ^ 1) 01 3 ^ (± & ^ ( The present invention has been completed by finding that EPS) has a lipid-related metabolic effect, and therefore, an object of the present invention is to contain a natural substance derived from the extract of Seriphoria laccerata mycelium culture medium as an active ingredient. To improve lipid-related metabolism, It is to provide a composition for preventing or treating lipid-related metabolic diseases.
본 발명의 다른 목적은 세리포리아 락세라타 균사체 배양액 추출물 유래의 천연물질을 함유하는， 지질 관련 대사 개선용 식품을 제공하는 것이다. 상기 목적을 달성하기 위하여， 본 발명은 세리포리아 락세라타 균사체 배양액 추출물 유래의 세포외다당체를 유효성분으로 함유하는, 지질 관련 대사 개선용 조성물을 제공한다.  Another object of the present invention is to provide a foodstuff for improving metabolism related to lipids, which contains a natural substance derived from the extract of Ceriporia laccerata mycelia. In order to achieve the above object, the present invention provides a composition for improving lipid-related metabolism containing an extracellular polysaccharide derived from the extract of the seriporia laccerata mycelium culture solution as an active ingredient.
상기 다른 목적을 달성하기 위하여， 본 발명은 세리포리아 락세라타 균사체 배양액 추출물 유래의 세포외다당체를 유효성분으로 함유하는， 지질 관련 대사성 질환의 예방 또는 치료용 조성물을 제공한다. , 상기 세포외다당체는 약 40-60 중량 %의 당과 약 30~40 중량 >의 단백질을 포.함하고 약 100-150 kDa의 분자량을 갖는 것일 수 있다. In order to achieve the above another object, the present invention provides a composition for the prevention or treatment of lipid-related metabolic diseases containing the extracellular polysaccharide derived from the extract of the seriporia laccerata mycelium culture medium as an active ingredient. The extracellular polysaccharide may be included. And also having a molecular weight of about 100-150 kDa protein of about 40 to 60% by weight and about 30 to 40 parts by weight per>.
상기 지질 관련 대사성 질환은 지방간， 고지혈증, 고콜레스테를혈증， 심혈관 질환， 동맥경화증 또는 지질 관련 대사증후군일 수 있다.  The lipid-related metabolic disease may be fatty liver, hyperlipidemia, hypercholesterolemia, cardiovascular disease, arteriosclerosis or lipid-related metabolic syndrome.
상기 또 다른 목적을 달성하기 위하여， 본 발명은 세리포리아 락세라타 균사체 배양액 추출물 유래의 세포외다당체를 함유하는， 지질 관련 대사 개선용 식품을 제공한다. 본 발명에 따른 세리포리아 락세라타 균사체 배양액 추출물 유래의 세포외다당체를 유효성분으로 함유하는 조성물은 지질 관련 대사 개선 및 지질 관련 대사성 질환의 예방 또는 치료에 매우 효과적으로 이용될 수 있다. 도면의 간단한 설명 본 발명의 상기 및 다른 목적과 특징들은 첨부된 도면과 함께 하기 본 발명의 설명으로부터 명확해질 것이다:  In order to achieve the above another object, the present invention provides a food-related lipid-improving metabolism containing the extracellular polysaccharide derived from the extract of the seriporia laccerata mycelium culture. The composition containing the extracellular polysaccharide derived from the extract of Seriporia laccerata mycelium culture medium according to the present invention as an active ingredient can be very effectively used for improving lipid-related metabolism and preventing or treating lipid-related metabolic diseases. BRIEF DESCRIPTION OF THE DRAWINGS The above and other objects and features of the present invention will become apparent from the following description of the invention in conjunction with the accompanying drawings:
도 1은 배양물 정제에 따른 EPS의 분자량을 측정한 그래프이다.  1 is a graph measuring the molecular weight of EPS according to the culture purification.
도 2 는 EPS 에 의한 간의 조직학적 형태 특성을 나타낸 현미경 사진이다. 발명의 상세한 설명 이하 본 발명에 대하여 보다 상세히 설명한다. 본 발명은 세리포리아 락세라타 ; r/a lacerata) 균사체 배양액 추출물 유래의 세포외다당체 (exopo lysacchar ide ; EPS)를 유효성분으로 함유하는， 지질 관련 대사 개선용 조성물을 제공한다. 2 is a microscope showing the histologic morphology of the liver by EPS It is a photograph. DETAILED DESCRIPTION OF THE INVENTION Hereinafter, the present invention will be described in more detail. The present invention is Ceriporia lac serrata; r / a lacerata) Provides a composition for improving lipid-related metabolism containing an extracellular polysaccharide (exopo lysacchar ide; EPS) derived from the mycelium culture extract.
또한， 본 발명은 세리포리아 락세라타 균사체 배양액 추출물 유래의 세포외다당체를 유효성분으로 함유하는, 지질 관련 대사성 질환의 예방 또는 치료용 조성물을 제공한다. 본 발명에 따른 조성물에 있어서，상기 세포외다당체는 약 40~60중량 %의 당과 약 30-40중량 ¾의 단백질， 약 40-50중량 %의 당과 약 32~38중량 %의 단백질 또는 약 43-47 중량 %의 당과 약 33~36 중량>의 단백질을 포함할 수 있고, 바람직하게는 약 45 중량 %의 당과 약 34 중량 ¾의 단백질을 포함할 수 있다. 상기 당은 만노오스， 갈락토오스 및 글루코오스를 함유할 수 있다.  In another aspect, the present invention provides a composition for the prevention or treatment of lipid-related metabolic diseases, containing the extracellular polysaccharide derived from the extract of the seriporia laccerata mycelium culture medium as an active ingredient. In the composition according to the present invention, the extracellular polysaccharide is about 40-60% by weight of sugar and about 30-40% by weight protein, about 40-50% by weight of sugar and about 32-38% by weight of protein or about 43-47 wt% sugar and about 33-36 wt% protein, and preferably about 45 wt% sugar and about 34 wt% protein. The sugar may contain mannose, galactose and glucose.
상기 세포외다당체는 약 100-150 kDa , 약 110~140 kDa 또는 약 115~125 kDa 의 분자량을 가질 수 있고, 바람직하게는 약 120 kDa 의 분자량을 가질 수 있다.  The extracellular polysaccharide may have a molecular weight of about 100-150 kDa, about 110-140 kDa or about 115-125 kDa, and preferably may have a molecular weight of about 120 kDa.
바람직한 하나의 구체예로서, 상기 세포외다당체는， (a) 세리포리아 락세라타 균사체를 액체 배양하여 세리포리아 락세라타 균사체 배양액을 제조하는 단계， (b)세리포리아 락세라타 균사체 배양액올 건조시켜 분말화하는 단계, 및 ( c) 세리포리아 락세라타 균사체 배양액 분말을 용매로 추출한 후 이를 여과하고 감압농축하는 단계를 포함하는 제조방법에 의하여 제조될 수 있다.  In one preferred embodiment, the extracellular polysaccharide is (a) liquid culture of the Ceriporia laccerata mycelium to prepare a culture medium of Ceriporia laccerata other mycelium, (b) Ceriporia laccerata mycelium The culture solution may be prepared by drying the powder, and (c) extracting the Ceriphoria laccerata mycelium culture powder with a solvent, followed by filtration and concentration under reduced pressure.
상기 (a) 단계에서의 세리포리아 락세라타 균사체의 액체 배양을 위한 배지는 설탕， 포도당, 전분， 수수분, 대맥분, 대두분， 황산마그네슘 (MgS04) , 1 인산칼륨 (K¾P04) , 2 인산칼륨 (K2HP04) 및 물을 포함하고, 수소이온농도가 ρΗ 4.5-6.0인 것일 수 있다. Liquid culture of the seriporia lacserata mycelium in step (a) The medium contains sugar, glucose, starch, hydrate, soy flour, soy flour, magnesium sulfate (MgS0 4 ), potassium phosphate (K¾P0 4 ), potassium diphosphate (K 2 HP0 4 ) and water, and hydrogen ion concentration May be ρΗ 4.5-6.0.
바람직한 하나의 구체예로세 상기 배지는, 설탕 1~2 중량 %， 포도당 0.2-1중량 %， 전분 0.2~1중량 ¾>, 수수분 0. 1-0.5중량 %, 대맥분 0. 1-0.5중량 %， 대두분 0.2-4중량 %， 황산마그네슴 (MgS04) 0.05~0.25증량 ¾, 1인산칼륨 (K¾P04) 0.05~0.25중량 2인산칼륨( ^04) 0.05~0.25중량¾및 물 92~98중량 %를 포함할 수 있다. Three the medium in one preferred embodiment, the sugar 1-2% by weight, 0.2 to 1% by weight glucose, starch, 0.2 to 1 wt ¾>, moisture can 0. 1-0.5% by weight, barley 0. 1-0.5 min Weight%, Soy flour 0.2-4 weight%, Magnesium sulfate (MgS0 4 ) 0.05 ~ 0.25 increase ¾, potassium phosphate (K¾P0 4 ) 0.05 ~ 0.25 weight potassium diphosphate (^ 0 4 ) 0.05 ~ 0.25 weight ¾ and water It may comprise 92 to 98% by weight.
상기 (a)단계에서의 액체 배양은 청색 LED광원 하에서 수행될 수 있고, 이산화탄소의 농도를 1， 000-2 ,ΟΟΟρριη으로 유지하여 수행될 수 있다.  The liquid culturing in step (a) may be performed under a blue LED light source, and may be performed by maintaining a concentration of carbon dioxide at 1,000-2, ΟΟΟρριη.
이때, 액체 배양은 20~25°C에서, 수소이온농도 (pH) 4.5-6.0, 광원은 청색 LED, 조도는 0.5 LUX 를 유지하며 공기는 0.5-1.5 kgf/cm2 으로 주입하고 이산화탄소의 농도는 1 , 000 2 , 000 ppm 으로 유지하면서 8~13 일간 수행될 수 있고, 22°C , pH5 , 1.0 kgf/cm2, 1 , 500 ppm 조건에서 10 일간 수행되는 것이 세포외다당체의 함량이 높으므로 바람직하다. At this time, the liquid culture at 20 ~ 25 ° C, hydrogen ion concentration (pH) 4.5-6.0, light source blue LED, illuminance maintains 0.5 LUX, air is injected into 0.5-1.5 kgf / cm 2 and the concentration of carbon dioxide It can be carried out for 8 to 13 days while maintaining at 1, 000 2,000 ppm, and 10 days at 22 ° C, pH5, 1.0 kgf / cm 2 , 1, 500 ppm conditions because of the high content of extracellular polysaccharides desirable.
상기 (a) 단계에서의 모균주는 PDA(Po to dextrose agar ) 배지 상태로 4°C에 보관중인 우량균주 1 개를, 삼각플라스크에 PDB(Potato dextrose broth) 배지를 사용하여 진탕배양기에서 25°C의 항온을 유지하며 7~9 일간 배양과정을 거친 것을 사용할 수 있다. 이때 접종원으로 투입될 균사체의 양은 배양할 용액의 양을 기준으로 0.5% 정도인 것이 바람직하다. 균사체량(%/10(½1 )이 높다고 세포외다당체의 함량도 같이 높아지는 것이 아니므로 배지 조성은 균사체의 성장에 가장 양호한 영양 비율 및 환경조건이 아닌， 세포외다당체의 함량을 가장 높게 형성시키는 선택적 배양조건을 적용하는 것이 바람직하다. 상기 배양액은 균사체와 수용액으로 분리 정제할 수 있다. 상기 분리 정제는 원심분리기로 균사체를 제거한 용액을 다중필터프레스 (Mul t i-SheetThe parent strain in the step (a) is a good strain stored at 4 ° C in the state of PDA (Po to dextrose agar) medium, 25 ° in shake incubator using PDB (Potato dextrose broth) medium in the Erlenmeyer flask It can be used to maintain a constant temperature of C and after 7 to 9 days incubation process. At this time, the amount of mycelia to be added to the inoculum is preferably about 0.5% based on the amount of the solution to be cultured. Since the high mycelial mass (% / 10 (½1)) does not increase the content of extracellular polysaccharides, the medium composition is selective to form the highest content of extracellular polysaccharides, not the best nutritional ratio and environmental conditions for the growth of mycelia. The culture medium may be separated and purified by the mycelium and the aqueous solution The separated purification is a multi-filter press (Mul t i-Sheet) to remove the mycelium with a centrifuge
Fi l ter Press)와 진동원심막분리기 (PALLSEP)로 반복하여 정제한 후 1 분간 자외선 (UV)을 조사할 수 있다. 또한, 산소를 제거한 후 밀봉 보관하는 것이 필요한데, 이는 용액속에 균사가 존재할 경우 균사의 성장으로 유호성분의 함량에 변화를 가져오기 때문이다. Filtration Press) and Vibration Centrifuge (PALLSEP) can be repeated and purified for 1 minute after UV (UV) irradiation. In addition, it is necessary to store and seal after removing oxygen. This is because the content is changed.
상기 (b) 단계에서는 상기 ) 단계에서 제조된 균사체 배양액을 진공건조 또는 동결건조시켜 분말화할 수 있다. 상기의 건조는 유효물질의 소멸을 방지하기 위해 40°C 이하의 저온, 바람직하게는 30°C 이하의 온도에서 48~96 시간 동안 수행되는 것이 바람직하다. 그리고, (b) 단계에서의 건조는 증발온도를 상대적으로 높게 설정하는 진공건조기보다 진공동결건조기를 사용하는 것이 유효물질 함량 변화가 최소화되므로 바람직하다. In step (b), the mycelia culture solution prepared in step) may be powdered by vacuum drying or lyophilization. The drying is preferably carried out for 48 to 96 hours at a low temperature of 40 ° C or less, preferably 30 ° C or less in order to prevent the disappearance of the active substance. And, in the step (b), it is preferable to use the vacuum freeze dryer rather than the vacuum dryer which sets the evaporation temperature relatively high, since the change of the effective substance content is minimized.
상기 (c) 단계에서는 (b) 단계에서 얻은 균사체 배양액 건조물을 용매로 추출하여 본 발명에 따른 조성물의 유효성분인 세포외다당체를 분리， 제조한다.■ 상기 과정은 건조 분말 5g 에 증류수 100 mL 을 첨가하여 잘 현탁한 후, 원심분리 (8，000 rpm , 20 min)하여 이의 상등액에 그 양의 2~3 배에 해당하는 차가운 알코올을 첨가하고 넁장고 (41： )에 넣어 12 시간 정치시킬 수 있다. 상기의 정치물에서 상등액만을 다시 원심분리 (8 , 000 rpm, 20 min)한 후, 침전물을 회수하여 조 (crude) 세포외다당체를 제조할 수 있다. 상기 추출물은 3C C 이하에서 진공동결건조하는 것이 바람직하다. 본 발명에 따른 세리포리아 락세라타 균사체 배양액 추출물 유래의 세포외다당체를 유효성분으로 함유하는 지질 관련 대사 개선 또는 지질 관련 대사성 질환의 예방 또는 치료용 조성물에는 통상적으로 사용되는 적절한 담체, 부형제 및 희석게가 더 포함될 수 있다. In step (c), the mycelium culture broth obtained in step (b) is extracted with a solvent to separate and prepare an extracellular polysaccharide which is an active ingredient of the composition according to the present invention. ■ The above process is suspended by adding 100 mL of distilled water to 5 g of dry powder, followed by centrifugation (8,000 rpm, 20 min) to add 2 ~ 3 times the amount of cold alcohol to the supernatant thereof. I can put it in django (41 :) and let it stand for 12 hours. After centrifugation (8, 000 rpm, 20 min) again only the supernatant from the stationary material, the precipitate can be recovered to prepare a crude extracellular polysaccharide. The extract is preferably freeze dried in 3C C or less. Suitable carriers, excipients, and diluents commonly used in compositions for the improvement of lipid-related metabolism or for the prevention or treatment of lipid-related metabolic diseases, which contain extracellular polysaccharides derived from the extract of Ceriporia laccerata mycelium culture medium according to the present invention. More crabs may be included.
상기 세포외다당체는 조성물 총 중량에 대하여 0. 1 내지 80 증량 %, 바람직하게는 0. 1 내지 50 중량 ¾>로 포함될 수 있다. 그러나, 가장 바람직한 추출물의 유효 함량은 조성물의 사용방법 및 목적에 따라 적절히 조절될 수 있다.  The extracellular polysaccharide may be included in an amount of 0.1 to 80% by weight, preferably 0.1 to 50% by weight, based on the total weight of the composition. However, the effective amount of the most preferred extract can be properly adjusted according to the method of use and purpose of the composition.
본 발명에 따른 조성물은 각각 통상의 방법에 · 따라 제형화하여 사용될 수 있다. 적합한 제형으로는 정제， 환제， 산제, 과립제, 당의정， 경질 또는 연질의 캡술제, 용액제, 현탁제 또는 유화액제, 주사제, 좌제 등이 있으나, 이에 한정되는 것은 아니다. 본 발명에 따른 조성물은 약학적으로 불활성인 유기 또는 무기 담체를 이용하여 적합한 제형으로 제조할 수 있다. 즉， 제형이 정게， 코팅된 정제, 당의정 및 경질 캡슐제인 경우 락토스, 수크로스， 전분 또는 그 유도체， 탈크, 칼슘 카보네이트， 젤라틴, 스테아르산 또는 그 염을 사용할 수 있다. 또한, 제형이 연질 캡술제의 경우에는 식물성 오일， 왁스， 지방， 반고체 및 액체의 폴리올이 사용 가능하다. 또한, 제형이 용액 또는 시럽 형태의 경우에는 물， 폴리을， 글리세를, 및 식물성 오일 둥이 사용될 수 있다. The compositions according to the present invention can be used to formulate, according to a conventional method, respectively. Suitable formulations include, but are not limited to, tablets, pills, powders, granules, dragees, hard or soft capsules, solutions, suspensions or emulsions, injections, suppositories, and the like. The composition according to the invention can be prepared in a suitable formulation using a pharmaceutically inert organic or inorganic carrier. That is, lactose, sucrose, starch or derivatives thereof, talc, calcium carbonate, gelatin, stearic acid or salts thereof may be used when the formulation is tablets, coated tablets, dragees and hard capsules. In addition, polyols of vegetable oils, waxes, fats, semisolids and liquids can be used when the formulation is a soft capsulant. In addition, water, poly, glycerol, and vegetable oil spouts may be used when the formulation is in solution or syrup form.
본 발명에 따른 조성물은 상기의 담체 외에도 보존제， 안정화제，습윤제， 유화제， 용해제， 감미제， 착색게， 삼투압 조절제 ,산화방지제 등을 더 포함할 수 있다.  The composition according to the present invention may further include a preservative, stabilizer, wetting agent, emulsifier, solubilizer, sweetener, coloring crab, osmotic pressure control agent, antioxidant and the like in addition to the carrier.
본 발명에 따른 조성물의 투여방법은 제형에 따라 용이하게 선택될 수 있으며, 경구 또는 비경구 투여될 수 있다. 투여량은 환자의 나이， 성별， 체중 병증의 정도， 투여경로에 따라 달라질 수 있으나 일반적으로 5 내지 500mg/kg의 양， 바람직하게는 100내지 250mg/kg의 양을 1일 1회 내지 3회로 나누어 투여할 수 있다. 그러나， 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.  The method of administering the composition according to the present invention can be easily selected according to the dosage form, and can be administered orally or parenterally. The dosage may vary depending on the patient's age, sex, severity of the disease and the route of administration, but in general, the amount of 5 to 500 mg / kg, preferably 100 to 250 mg / kg, divided once to 3 times a day May be administered. However, the above dosage does not limit the scope of the present invention in any aspect.
본 발명에 따른 조성물은 우수한 지질 관련 대사 개선 효과를 제공할 뿐만 아니라 약물에 의한 독성 및 부작용도 거의 없어 지질 관련 대사성 질환의 치료 목적뿐만 아니라 예방 목적으로 장기간 복용시에도 안심하고 사용할 수 있다.  The composition according to the present invention not only provides an excellent lipid-related metabolic improvement effect but also has little toxicity and side effects due to the drug, and thus can be used safely for long-term administration as well as for the purpose of preventing lipid-related metabolic diseases.
상기 지질 관련 대사성 질환은 지방간， 고지혈증， 고콜레스테롤혈증, 심혈관 질환 동맥경화증 또는 지질 관련 대사증후군일 수 있으며， 이에 한정되는 것은 아니다. 또한, 본 발명은 세리포리아 락세라타 균사체 배양액 추출물 유래의 세포외다당체를 함유하는, 지질 관련 대사 개선용 식품을 제공한다.  The lipid-related metabolic disease may be fatty liver, hyperlipidemia, hypercholesterolemia, cardiovascular disease arteriosclerosis or lipid-related metabolic syndrome, but is not limited thereto. In another aspect, the present invention provides a food for improving lipid-related metabolism, containing the extracellular polysaccharide derived from the extract of Seriphoria laccerata mycelium culture solution.
본 발명에 따른 식품은 분말, 과립， 정제, 캡슐 또는 음료의 형태일 수 있고， 캔디， 초콜릿， 음료, 껌， 차， 비타민복합체 건강보조식품 또는 건강기능식품일 수 있다. Food according to the invention may be in the form of powder, granules, tablets, capsules or beverages, candy, chocolate, beverages, gum, tea, vitamin complex dietary supplements or It may be a dietary supplement.
이때， 상기 식품 중의 본 발명에 따른 세포외다당체는 일반적으로 전체 식품 중량의 0.01내지 50중량 %,바람직하게는 0.1내지 20중량 %으로 포함될 수 있고 건강 음료 조성물의 경우 100ml를 기준으로 0.02내지 10g, 바람직하게는 0.3 내지 lg의 비율로 포함할 수 있다.  At this time, the extracellular polysaccharide according to the present invention in the food in general may be included in 0.01 to 50% by weight, preferably 0.1 to 20% by weight of the total food weight and 0.02 to 10g based on 100ml for the health beverage composition, Preferably it may be included in the ratio of 0.3 to lg.
상기 식품은 본 발명의 세포외다당체와 함께 식품학적으로 허용가능한 식품 보조 첨가제를 더 포함할 수 있다. 이하， 본 발명을 하기 실시예에 의하여 더욱 상세하게 설명한다. 단， 하기 실시예는 본 발명을 예시하기 위한 것일 뿐, 본 발명꾀 범위가 이들만으로 한정되는 것은 아니다.  The food may further comprise a food supplement acceptable food additives with the extracellular polysaccharide of the present invention. Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the following examples are only for illustrating the present invention, and the scope of the present invention is not limited thereto.
[실시예] 제조예 1. 세리포리아 락세라타 배양액 추출물 유래의 세포외다당체의 제조 EXAMPLES Preparation Example 1 Preparation of Extracellular Polysaccharides from Ceriporia laccerata Culture Extract
1.1 세리포리아 락세라타 배양액의 제조 경북 상주시에서 채취한 참나무 변제부 속에서 분리한 세리포리아 락세라타를 계대배양을 통해 육성한 모균을 -8CTC에 넁동보관 하였고， 보관중인 균주를 PDA(Potato dextrose agar) 배지 (87 플라스틱 배양구; Di fco, Becton Dickinson and Company) 에서 2~3 회 계대 후 층분한 수량의 완전한 균주만을 4°C 냉장고에 보관하여 사용하였다. 그리고, 삼각플라스크에 PDB(Potato dextrose broth)배지 (Di fco, Becton Di ckinson and Company) 600ml를 조성한 후， PDA 배양균주 1 개를 넣고 8 일간 진탕배양하였다. 그리고， 설탕1.1 Preparation of Ceriporia laccerata Cultures Ceriphoria laccerata isolated from oak reimbursements collected in Sangju, Gyeongbuk, were grown by subculture and stored at -8CTC. Potato dextrose agar) medium (87 plastic cultures; Di fco, Becton Dickinson and Company) after 2-3 passages were used to store only strains in complete quantities in 4 ° C refrigerator. Then, 600 ml of PDB (Potato dextrose broth) medium (Di fco, Becton Di ckinson and Company) was prepared in an Erlenmeyer flask, and one PDA culture strain was added thereto, followed by shaking culture for 8 days. And sugar
1.5중량 %， 포도당 0.5증량 %， 감자전분 0.5중량 %， 수수분 0.25중량 %， 대맥분1.5% by weight, 0.5% by weight of glucose, 0.5% by weight of potato starch, 0.25% by weight of water, wheat flour
0.25 중량 ¾, 대두분 0.75 증량 %, 황산마그네슘 (MgS04 ) 0.05 중량 %， 1인산칼륨 ( ¾P04 ) 0.05중량 %ᅳ 2인산칼튬 (K2HP04) 0.05중량 %및 물 96.85중량 ¾>를 포함하는 액체 배양 배지를 800L 발효조에서 121°C, 1.5 kgf/cm2로 20 분간 살균한 후， 23°C로 넁각한 상태에서 스타터로 사용할 PDB 배양균주 600 ml 를 접종하고, 공기를 0.5~1.5 kgf/cm2 로 통기시키면서, 이산화탄소의 농도는 1,000-2,000 ppm으로 세리포리아 락세라타 균사체를 23°C의 항온에서 10 일간 액체 배양함으로써 세리포리아 락세라타 균사체 배양액을 제조하였다. 0.25 weight ¾, soy flour 0.75% increase, magnesium sulfate (MgS0 4 ) 0.05% by weight, Potassium phosphate (¾P0 4 ) 0.05% by weight ᅳ 0.05% by weight of potassium diphosphate (K 2 HP0 4 ) and 96.85% by weight of water were added to a liquid culture medium at 800 ° C fermenter at 121 ° C, 1.5 kgf / cm 2 . After sterilizing for 3 minutes, inoculate 600 ml of PDB culture strain to be used as a starter at 23 ° C, and ventilate air at 0.5 to 1.5 kgf / cm 2 , and the concentration of carbon dioxide is 1,000-2,000 ppm. Ceriporia lacserata mycelium cultures were prepared by liquid incubating the lacserata mycelium at a constant temperature of 23 ° C. for 10 days.
1.2 세리포리아 락세라타 배양액 추출물로부터 EPS의 제조 제조된 세리포리아 락세라타 균사체 배양액을 진공동결건조기를 이용하여 25°C의 저온에서 72시간 동안 동결건조시켜 분말화하였다. 건조 분말 5g에 증류수 100ml 를 첨가하여 잘 현탁한 후, 원심분리 (8,000rPm, 20분)하여 이의 상등액에 그 양의 2~3 배에 해당하는 차가운 알코을을 첨가하고 냉장고 (4°C)에 넣어 12 시간 정치시켰다. 상기의 정치물에서 상등액만을 다시 원심분리 (8,000rpm, 20 분)한 후, 침전물을 회수하여 조 (crude) EPS 를 추출하였다. 조 EPS 를 동결건조기에서 72 시간 건조시켜 완전한 EPS 를 획득하였다. 실시예 1. EPS의 특성 평가 1.2 Preparation of EPS from Ceriporia laccerata Culture Extract The prepared Ceriporia laccerata mycelium culture was powdered by lyophilization for 72 hours at 25 ° C. using a vacuum freeze dryer. Suspend well by adding 100 ml of distilled water to 5 g of dry powder, and centrifuging (8,000r Pm , 20 minutes) to add a cold alcohol corresponding to 2 to 3 times the amount of the supernatant thereof to a refrigerator (4 ° C). Let stand for 12 hours. Only the supernatant was again centrifuged (8,000 rpm, 20 minutes) in the stationary material, and the precipitate was recovered to extract crude EPS. The crude EPS was dried for 72 hours in a freeze dryer to obtain complete EPS. Example 1 Evaluation of Characteristics of EPS
1,1 겔투과 크로마토그래피 (Gel Permeation Chromatography, GPC)를 이용한 EPS의 분자량 측정 제조예 1 에서 제조한 EPS 를 0.1 M Na2S04/0.05 M NaN3 (빙초산 (glacial acetic acid)으로 PH 를 4 로 조정) 용액에 1% 되도록 녹인' 다음, 원심분리 후 상층액 만올 0.45 μιη 시린지 필터 (syringe filter)로 여과하여 GPC 로 분석하였다. 1,1 Gel Permeation Chromatography (Gel Permeation Chromatography, GPC) of the molecular weight measurement using the EPS prepared in Preparation Example 1, the EPS 0.1 M Na 2 S0 4 /0.05 M NaN 3 ( glacial acetic acid (glacial acetic acid) to the P H adjusted to 4) were dissolved to 1% in the solution and, then, centrifuged and filtered through a supernatant manol 0.45 μιη syringe filter (syringe filter), and analyzed by GPC.
분석조건은 검출기로 굴절지수를 이용하였으며 , GPC칼럼은 OHpak SB 805 HQ(Shodex, Japan)를 이용하여 이동상을 0.1 M Na2S04/0.05 M NaN3 (빙초산으로 pH를 4로 조정)로 유속은 1.0 mL/min의 속도로 흘려주었다. 표준곡선은 각기 다른 분자량 (130， 400， 770 및 1200 kDa)을 가진 덱스트란 (Amer ican Polymer Corporation, USA)을 이용하여 작성하였으며, 굴절지수 (refract ive index, RI) 측정기 Knauer K_2310(Germany)를 이용하여 EPS의 분자량을 측정하였다 (표 1). The analytical conditions were the index of refraction and the GPC column was OHpak SB 805. Using HQ (Shodex, Japan), the mobile phase was flowed into 0.1 M Na 2 SO 4 /0.05 M NaN 3 (adjusted pH to 4 with glacial acetic acid) at a rate of 1.0 mL / min. Standard curves were prepared using Amer ican Polymer Corporation, USA, with different molecular weights (130, 400, 770, and 1200 kDa), and Knauer K_2310 (Germany), a refractive index (RI) measuring instrument. The molecular weight of EPS was measured (Table 1).
[표 1] TABLE 1
Figure imgf000011_0001
Figure imgf000011_0001
그 결과， EPS의 분자량은 약 120 kDa인 것으로 나타났다 (도 1).  As a result, the molecular weight of EPS was found to be about 120 kDa (FIG. 1).
'  '
1.2 EPS의 당 및 단백질 함량 측정  1.2 Determination of sugar and protein content in EPS
EPS 를 2 차 정제하고 단백질 가수분해 효소를 처리하여 당 및 단백질 함량을 측정하였다. EPS was purified twice and treated with proteolytic enzymes to determine sugar and protein content.
구체적으로， 1차 정제된 EPS를 다시 증류수에 녹이고 원심분리 (8,000rpm, Specifically, the first purified EPS is dissolved again in distilled water and centrifuged (8,000rpm,
20 분)하여 상등액을 분리한 후， 분리된 상등액에 그 양의 2~3 배에 해당하는 차가운 알코올을 첨가하고 넁장고 (4°C)에 넣어 12 시간 정치시켰다. 상기의 정치물에서 상등액만을 다시 원심분리 (8,000rpmᅳ 20 분)한 후， 침전물을 회수하여 2 차 정제된 EPS 를 획득하였다. 다음으로， 단백질 가수분해 효소인 알칼레이즈 (alcalase)를 0.5¾>의 농도로 50°C에서 30분간 처리하였다. 20 minutes), the supernatant was separated, and then cold alcohol corresponding to 2-3 times the amount was added to the separated supernatant and placed in a steamed dish (4 ° C) for 12 hours. After centrifugation (8,000 rpm 20 min) again only the supernatant from the stationary material, the precipitate was recovered to obtain a second purified EPS. Next, alkalase, a proteolytic enzyme, was treated at 50 ° C. for 30 minutes at a concentration of 0.5¾>.
당 함량은 페놀-황산법 (pheno卜 sulfuric acid method)에 의해 측정하였다. 농도별로 희석한 시료 1 raL 에 80% 페놀을 25 yL 첨가함 후 황산을 2.5 mL 첨가하여 실온에서 넁각하고 465 nm 에서 흡광도를 측정하여 계산하였다. 단백질 함량은 BCA 방법 (Smi th P , et al . , Analytical Biochemistry, 150( 1)：76-85 ( 1985) 참고)에 의해 측정되었고 표준품으로 소혈청 알부민을 사용하였다. Sugar content was measured by the phenol- sulfuric acid method (pheno 卜 sulfuric acid method). After adding 25 yL of 80% phenol to 1 raL of each sample diluted by concentration, 2.5 mL of sulfuric acid was added, and the mixture was absorbed at room temperature and the absorbance was measured at 465 nm. Protein content was measured by the BCA method (Smi th P, et al., Analytical Biochemistry, 150 (1): 76-85 (1985)) and bovine serum albumin was used as a standard.
그 결과， 아래 표 2 와 같이， 당 함량은 45~51 중량 %이고 단백질 함량은 33~34 중량 %인 것으로 나타났다.  As a result, as shown in Table 2 below, the sugar content is 45 ~ 51% by weight and the protein content was found to be 33 ~ 34% by weight.
[표 2] 총단백질 함량 수을 (%) 총당함량 (%) [Table 2] Total protein content number (%) Total sugar content (%)
( )  ()
EPS 1.22+0.03 45.32+1.41 34.17±0.73  EPS 1.22 + 0.03 45.32 + 1.41 34.17 ± 0.73
2차 정제된 EPS 0.78±0.01 50.49±0.52 33.50+2.79 효소 처리된 EPS* 0.24±0.06 51.39+1.32 34.61+1.51 Secondary purified EPS 0.78 ± 0.01 50.49 ± 0.52 33.50 + 2.79 Enzyme-treated EPS * 0.24 ± 0.06 51.39 + 1.32 34.61 + 1.51
*효소 처리: 알칼레이즈 0.5%, 50X, 30분. * Enzyme treatment: Alcalase 0.5%, 50X, 30 minutes.
각수치는 평균 ±SE (n≥3)임.  Angular values are mean ± SE (n≥3).
또한， EPS 의 당 구성 분석 결과, EPS 는 주로 만노오스， 갈락토오스 및 글루코오스를 함유하고 있는 것으로 나타났다. In addition, as a result of the sugar composition analysis of EPS, EPS mainly contained mannose, galactose and glucose.
실시예 2. EPS의 지질 대사 개선 효과 검증 Example 2. Verification of Lipid Metabolism Improvement Effect of EPS
2. 1 실험 방법 2.1 Experimental Method
세리포리아 락세라타 배양액 추출물 유래의 EPS 의 지질 대사 개선 효과를 조사하기 위하여， 상기 제조예 1 에서 제조된 EPS 와 동물모델인In order to investigate the lipid metabolism-improving effect of EPS derived from the extract of Ceriporia laccerata culture, the EPS and animal model prepared in Preparation Example 1
C57BL/Ksj (BL/Ls) homozygous di abet i c (db/db)마우스를 사용하였다.본 연구에 사용한 db/db마우스는 30-40 g정도의 6주령 수컷이었으며， Japan SIX Inc .에서 생산하여 중앙실험동물 (주)를 통하여 공급받았으며 , 약 7 일간의 검역순화 및 적응기간 후 체중과 혈당을 측정하여 시험실시에 적합하고 일반증상에 이상이 없는 건강한 동물 30마리를 선별하였다. C57BL / Ksj (BL / Ls) homozygous di abet ic (db / db) mice were used. The db / db mice used in this study were 30-40 g 6-week-old males, produced by Japan SIX Inc. It was supplied through experimental animal Co., Ltd. After the acclimation period, the body weight and blood glucose were measured to select 30 healthy animals suitable for the test and no abnormal symptoms.
실험동물은 음성 대조군 ("DM그룹 "), EPS저용량군 (150mg/kg, "DM-EX0150 그룹 ")， EPS 고용량군 (300 mg/kg, "DM-EX0300 그룹") 및 양성대조군 (메트포르민 (metformin)-300 mg/kg, "DM-MET300 그룹") 등 4 군의 혈당 및 체중이 균등하도록 랜덤으로 나누어 6 주 동안 사육하였다. 또한 정상 대조군 ("NC 그룹")도 6 마리를 동일한 조건에 6 주 동안 사육하였다. 모든 시험물질 및 양성 대조물질은 매일 동일한 시간에 경구투여하였으며， 정상 대조군 및 음성 대조군은 물을 경구투여하였다. 실험동물의 식이는 시판용 실험동물 고형사료 (Samtaco co. ltd. , Korea)를 공급하였고, 물은 자유 섭취시켰다. 동물 사육실의 사육조건은 12 시간 명암주기 (오전 8 시〜오후 8 시 조명), 온도 23±3°C, 상대습도 50±10%가 되도록 조절하였다. 、The experimental animals were negative control ("DM group"), EPS low dose group (150 mg / kg, "DM-EX0150 group"), EPS high dose group (300 mg / kg, "DM-EX0300 group") and positive control group (metformin ( Four groups, including metformin) -300 mg / kg and “DM-MET300 group”), were randomly divided so that the blood sugar and body weight were equally distributed for 6 weeks. In addition, the normal control group (“NC group”) was also housed 6 animals for 6 weeks under the same conditions. All test and positive controls were orally administered at the same time every day, and normal and negative controls were orally administered with water. The diet of experimental animals was supplied with commercial experimental animal solid feed (Samtaco co. Ltd., Korea), and water was freely ingested. The breeding conditions of the animal breeding room were adjusted to have a 12-hour contrast cycle (lighting from 8 am to 8 pm), a temperature of 23 ± 3 ° C, and a relative humidity of 50 ± 10%. 、
EPS 투여 6 주 후의 db/db 마우스를 회생한 후 간의 조직학적 형태 특성을 관찰하고， 혈액 내의 지질 수준을 측정하였다. Db / db mice 6 weeks after the EPS administration were regenerated and histologic morphological characteristics of the liver were observed and lipid levels in the blood were measured.
2.2 간의 조직학적 형태 특성 헤마톡실린 및 에오신으로 간을 염색하여 간의 조직학적 형태 특성을 현미경으로 관찰하였다. 그 결과， 간 지질이 음성 대조군인 DM 그룹에서 급격히 증가한 반면， EPS 투여 그룹 (즉, DM-EX0150 그룹 및 DM-EX0300 그룹)에서는 유의적으로 감소하는 것으로 나타났다 (도 2). Histological Morphological Characteristics of Liver The liver was stained with hematoxylin and eosin to observe the histologic morphological characteristics of the liver. As a result, hepatic lipids increased sharply in the DM group, which was a negative control, while significantly decreased in the EPS administration group (ie, DM-EX0150 group and DM-EX0300 group) (FIG. 2).
이를 통해， EPS 가 db/db 마우스에서 간 지질의 합성을 억제한다는 점을 확인할 수 있었다. 2.3 혈액 내의 지질 수준 총 콜레스테를 및 트리글리세라이드의 함량은 정상 대조군인 NC 그룹보다 음성 대조군인 DM그룹에서 약 2배 정도 높았지만， EPS투여 그룹 (즉， DM-EX0300 그룹)에서 유의적으로 감소하는 것으로 Through this, it was confirmed that EPS inhibits the synthesis of liver lipids in db / db mice. 2.3 Lipid Levels in Blood Total cholesterol and triglyceride contents were about twice as high in the DM group as the negative control group than in the NC group as the normal control group. DM-EX0300 group)
HDL- LDL-HDL- LDL-
. 총 콜레스테를 트리글리세라이드 . Total Cholesterol Triglycerides
그룹 (mg/dL) 콜레스테를 콜레스테를  Group (mg / dL) cholesterol
(mg/dL)  (mg / dL)
(mg/dL) (mg/dL) (mg / dL) (mg / dL)
NC 58.55±5.19 49.96±3.1 65.98±15.42 2G.63±0.95NC 58.55 ± 5.19 49.96 ± 3.1 65.98 ± 15.42 2G.63 ± 0.95
DM 111.12±11.15 t†t i07.69±6,40††† 107.48±4.57† 2l.84±0.9DM 111.12 ± 11.15 t † t i07.69 ± 6,40 ††† 107.48 ± 4.57 † 2l.84 ± 0.9
DM-EXO DM-EXO
92 01：±11.1 S3.0?±9.50 130,49±7.21 16.18il,76* 150 92 01 ： ± 11.1 S3.0? ± 9.50 130,49 ± 7.21 16.18il, 76 * 150
DM-EXO  DM-EXO
92,30±i3.66 83.99f5.45* 140,02±10; 7* 14.69+2.06** 300 92,30 ± i3.66 83.99f5.45 * 140,02 ± 10; 7 * 14.69 + 2.06 ** 300
DM- ET  DM-ET
84.6818· 05* 73.81±9.]'9" I34.80il0.12 18;) 5±1.40 300 각값숀평,균 ±$E일. 84.6818 · 05 * 73.81 ± 9.] ' 9 "I34.80il0.12 18;) 5 ± 1.40 300 Each value Sean average, average ± $ E day.
t , † f † p<.05v .001 vs. NG, t, † f † p <.05v .001 vs. NG,
*, ** p<.05, .01 vs. DM (각그룹당 n=6).  *, ** p <.05, .01 vs. DM (n = 6 per group).
이를 통해， EPS 가 db/db 마우스에서 혈중 지질 대사를 개선시킨다는 확인할 수 있었다. Through this, it was confirmed that EPS improves blood lipid metabolism in db / db mice.

Claims

특허청구의 범위 Scope of claim
1. 세리포리아 락세라타 (Cer ipor i a lacerata) 균사체 배양액 추출물 유래의 세포외다당체 (exopolysacchar ide)를 유효성분으로 함유하는， 지질 관련 대사 개선용 조성물. 1. A composition for improving lipid-related metabolism, which contains an extracellular polysaccharide (exopolysacchar ide) derived from Cer ipor i a lacerata mycelium culture extract.
2. 세리포리아 락세라타 균사체 배양액 추출물 유래의 세포외다당체를 유효성분으로 함유하는， 지질 관련 대사성 질환의 예방 또는 치료용 조성물. 2. A composition for the prevention or treatment of lipid-related metabolic diseases, which contains an extracellular polysaccharide derived from the extract of Seriphoria laccerata mycelia culture medium as an active ingredient.
3. 제 1 항 또는 제 2 항에 있어서， 3. Paragraph 1 or 2 above,
상기 세포외다당체는 40~60 중량 %의 당과 30~40 중량 %의 단백질을 포함하고 100~150 kDa의 분자량을 갖는 것을 특징으로 하는 조성물.  The extracellular polysaccharide comprises a composition of 40 to 60% by weight of sugar and 30 to 40% by weight of protein and has a molecular weight of 100 ~ 150 kDa.
4. 제 3 항에 있어서， 4. The method of paragraph 3,
상기 세포외다당체는 43~47 중량 ¾의 당과 33~36 중량 ¾의 단백질을 포함하고 115-125 kDa의 분자량을 갖는 것을 특징으로 하는 조성물.  The extracellular polysaccharide comprises a sugar of 43 to 47 weight ¾ and a protein of 33 to 36 weight ¾ and has a molecular weight of 115-125 kDa.
5. 제 3 항에 있어서 , 5. The method of paragraph 3,
상기 당은 만노오스， 갈락토오스 및 글루코오스를 함유하는 것을 특징으로 하는 조성물.  Wherein the sugar contains mannose, galactose and glucose.
6. 제 1 항 또는 제 2 항에 있어서, 6. Paragraph 1 or 2 above,
상기 세포외다당체는， (a) 세리포리아 락세라타 균사체를 액체 배양하여 세리포리아 락세라타 균사체 배양액을 제조하는 단계, (b) 세리포리아 락세라타 균사체 배양액을 건조시켜 분말화하는 단계， 및 (c)세리포리아 락세라타 균사체 배양액 분말을 용매로 추출한 후 이를 여과하고 감압농축하는 단계를 포함하는 제조방법에 의하여 제조된 것을 특징으로 하는 조성물. The extracellular polysaccharide is prepared by (a) liquid culture of the seriphoria laccerata mycelium to prepare a culture medium of the seriphoria laccerata mycelium, and (b) drying and powdering the seriporia laccerata mycelium culture medium. Step, and (c) extracting the seriporia laccerata mycelium culture powder with a solvent and then filtering it. Composition prepared by a manufacturing method comprising the step of concentration under reduced pressure.
7. 제 6 항에 있어서， 7. The method of paragraph 6,
상기 액체 배양을 위한 배지는 설탕， 포도당 전분， 수수분， 대맥분, 대두분， 황산마그네슘 (MgS04) , 1인산칼륨 (K¾P04) , 2인산칼륨 (K2HP04) 및 물을 포함하고， 수소이온농도가 ρΗ 4.5-6.0 인 것을 특징으로 하는 조성물. The medium for culturing the liquid includes sugar, glucose starch, sorghum, soybean meal, soy flour, magnesium sulfate (MgS0 4 ), potassium monophosphate (K¾P0 4 ), potassium diphosphate (K 2 HP0 4 ) and water ， The composition, characterized in that the hydrogen ion concentration is ρΗ 4.5-6.0.
8. 제 6 항에 있어서， 8. The method of paragraph 6,
상기 액체 배양은 청색 LED 광원 하에서 수행되고， 이산화탄소의 '농도를 l , 000~2 , 000ppm으로 유지하여 수행되는 것을 특징으로 하는 조성물. The liquid culture was carried out in the composition characterized in that the blue LED light source is, the "concentration of carbon dioxide, l, performing 000 to 2, and by keeping the 000ppm.
9. 제 1 항 또는 제 2 항에 있어세 9. In accordance with paragraph 1 or 2
상기 세포외다당체는 조성물 총 중량에 대하여 0. 1 내지 80 중량 %로 포함되는 것을 특징으로 하는 조성물.  The extracellular polysaccharide is a composition, characterized in that it comprises 0.1 to 80% by weight relative to the total weight of the composition.
10. 제 2 항에 있어서， 10. The method of paragraph 2,
상기 지질 관련 대사성 질환은 지방간, 고지혈증， 고콜레스테를혈증, 심혈관 질환， 동맥경화증 또는 지질 관련 대사증후군인 것을 특징으로 하는 조성물.  The lipid-related metabolic disease is fatty liver, hyperlipidemia, hypercholesterolemia, cardiovascular disease, atherosclerosis or lipid-related metabolic syndrome composition, characterized in that.
11. 세리포리아 락세라타 균사체 배양액 추출물 유래의 세포외다당체를 함유하는， 지질 관련 대사 개선용 식품. 11. Food for improving metabolism related to lipids, which contains extracellular polysaccharide derived from extract of Seriphoria laccerata mycelium culture solution.
12. 제 11 항에 있어서， 12. The method of clause 11,
상기 식품은 분말， 과립, 정제 캡슐 또는 음료의 형태인 것을 특징으로 하는, 지질 관련 대사 개선용 식품. The food is characterized in that the form of powder, granules, tablet capsules or beverages Foods for improving metabolism related to lipids.
13. 제 11 항에 있어서, 13. The method of clause 11, wherein
상기 식품은 캔디, 초콜릿， 음료, 껌, 차, 비타민복합체, 건강보조식품 또는 건강기능식품인 것을 특징으로 하는， 지질 관련 대사 개선용 식품.  The food is candy, chocolate, beverages, gum, tea, vitamin complexes, health supplements or health functional foods, characterized in that the lipid-related metabolism improving food.
PCT/KR2014/006826 2014-07-14 2014-07-25 Composition for improving lipid-related metabolism comprising as active ingredient exopolysaccharide derived from extract from culture medium of ceriporia lacerata WO2016010183A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2014-0088652 2014-07-14
KR1020140088652A KR20160008431A (en) 2014-07-14 2014-07-14 Composition for improvement of lipid-related metabolic function comprising exopolysaccharide derived from ceriporia lacerata culture broth extracts as an active ingredient

Publications (1)

Publication Number Publication Date
WO2016010183A1 true WO2016010183A1 (en) 2016-01-21

Family

ID=55078666

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2014/006826 WO2016010183A1 (en) 2014-07-14 2014-07-25 Composition for improving lipid-related metabolism comprising as active ingredient exopolysaccharide derived from extract from culture medium of ceriporia lacerata

Country Status (2)

Country Link
KR (1) KR20160008431A (en)
WO (1) WO2016010183A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10702564B2 (en) 2014-11-03 2020-07-07 Fugenbiopharma Co., Ltd. Blood pressure lowering composition containing as active ingredient exopolysaccharide produced by means of ceriporia lacerata

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101691975B1 (en) * 2016-02-16 2017-01-02 (주)퓨젠바이오농업회사법인 Pharmaceutical composition for the prevention or treatment of neurodegenerative brain diseases comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient
KR101969433B1 (en) 2018-10-12 2019-04-17 김병천 Composition comprising product of two stage cultivation using Ganoderma applanatum and Ceriporia lacerata K1 mycelium for preventing or treating diabetes mellitus
KR101981571B1 (en) 2018-10-12 2019-05-24 김병천 Composition comprising product of two stage cultivation using Ganoderma applanatum and Ceriporia lacerata K1 mycelium for preventing or treating hepatic injury

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101031605B1 (en) * 2010-11-11 2011-04-27 김병천 Manufacturing method of culture extract of ceriporia lacerata for the therapy of diabetic diseases and culture extract of ceriporia lacerata using the same
CN103173357A (en) * 2011-12-22 2013-06-26 高冬 Ceriporia lacerata and application thereof
US20140193454A1 (en) * 2013-01-09 2014-07-10 Byoung Cheon KIM Method from preparing ceriporia lacerata culture extract and pharmaceutical composition for prevention or treatment of diabetes and diabetic complications comprising ceriporia lacerata culture extract as active ingredient

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101031605B1 (en) * 2010-11-11 2011-04-27 김병천 Manufacturing method of culture extract of ceriporia lacerata for the therapy of diabetic diseases and culture extract of ceriporia lacerata using the same
CN103173357A (en) * 2011-12-22 2013-06-26 高冬 Ceriporia lacerata and application thereof
US20140193454A1 (en) * 2013-01-09 2014-07-10 Byoung Cheon KIM Method from preparing ceriporia lacerata culture extract and pharmaceutical composition for prevention or treatment of diabetes and diabetic complications comprising ceriporia lacerata culture extract as active ingredient

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KIM, J. E. ET AL.: "Hyperglycemic effect of submerged culture extract of Ceriporia lacerata in streptozotocin-induced diabetic rats", FOOD SCIENCE AND BIOTECHNOLOGY, vol. 21, no. 6, 2012, pages 1685 - 1693 *
KIM, JI EUN: "Production of exopolysaccharides by submerged culture of Ceriporia lacerata and their anti-diabetic effect", FOOD SCIENCE & TECHNOLOGY, September 2013 (2013-09-01), pages 1 - 127 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10702564B2 (en) 2014-11-03 2020-07-07 Fugenbiopharma Co., Ltd. Blood pressure lowering composition containing as active ingredient exopolysaccharide produced by means of ceriporia lacerata

Also Published As

Publication number Publication date
KR20160008431A (en) 2016-01-22

Similar Documents

Publication Publication Date Title
KR101852840B1 (en) Hepatoprotective composition comprising enzyme treated larva
EP3231437B1 (en) Aging inhibitor
Choudhury et al. Effects of Pleurotus ostreatus on blood pressure and glycemic status of hypertensive diabetic male volunteers
WO2016010183A1 (en) Composition for improving lipid-related metabolism comprising as active ingredient exopolysaccharide derived from extract from culture medium of ceriporia lacerata
KR100787633B1 (en) Tea and Tea Manufacturing Method for Improving Liver Function and Curing of Hangover
WO2016010182A1 (en) Composition for improving liver function comprising as active ingredient exopolysaccharide derived from extract from culture medium of ceriporia lacerata
KR101296995B1 (en) Fermented product comprising fermented rice bran and rice germ by lactobacillus and preparation method thereof
WO2003101466A1 (en) Rubrofusarin glycoside-containing composition
KR101552970B1 (en) Composition for improving liver function or protecting liver damage Comprising Allium Hookeri Extract
JP2005213211A (en) Agent for inhibiting increase of blood glucose level
KR101712590B1 (en) Composition for relieving fatigue comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient
EP3117825A1 (en) Oral formulation comprising berberine and morus alba extract
KR20160063941A (en) Antioxidant composition comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient
KR101682108B1 (en) Composition for blood flow improvement comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient
KR20140066317A (en) Food for improving liver function comprising black rice culture of lentinus edodes mycelia adding hovenia dulcis extract as effective component
KR101682093B1 (en) Blood pressure reducing composition comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient
JP2006182706A (en) Agent for increasing adiponectin amount in blood
Fukuda Walnut polyphenols: Structures and functions
KR20120107254A (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES MELLITUS COMPRISING α-GLUCOSIDASE INHIBITOR AND BREWER&#39;S DRIED YEAST
KR101737626B1 (en) Composition for immunosuppression comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient
KR101655882B1 (en) Composition for eliminating hangover comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient
JP2015097511A (en) Production method of polyphenol derivative, and food and medicinal composition containing polyphenol derivative
KR101691972B1 (en) Pharmaceutical composition for the prevention or treatment of a cancer comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient
US11173187B2 (en) Concentrated oil-based polyphenol composition and a method of producing the oil-based polyphenol composition
JP2014240366A (en) Therapeutic agent of arteriosclerosis with low-molecular fraction of grifola gargal extract

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14897674

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 28/07/2017)

122 Ep: pct application non-entry in european phase

Ref document number: 14897674

Country of ref document: EP

Kind code of ref document: A1